JP2005538082A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538082A5
JP2005538082A5 JP2004521565A JP2004521565A JP2005538082A5 JP 2005538082 A5 JP2005538082 A5 JP 2005538082A5 JP 2004521565 A JP2004521565 A JP 2004521565A JP 2004521565 A JP2004521565 A JP 2004521565A JP 2005538082 A5 JP2005538082 A5 JP 2005538082A5
Authority
JP
Japan
Prior art keywords
stratum corneum
use according
patient
skin
botulinum toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004521565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538082A (ja
Filing date
Publication date
Priority claimed from US10/194,805 external-priority patent/US20040009180A1/en
Application filed filed Critical
Publication of JP2005538082A publication Critical patent/JP2005538082A/ja
Publication of JP2005538082A5 publication Critical patent/JP2005538082A5/ja
Pending legal-status Critical Current

Links

JP2004521565A 2002-07-11 2003-07-08 経皮ボツリヌス毒素組成物 Pending JP2005538082A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/194,805 US20040009180A1 (en) 2002-07-11 2002-07-11 Transdermal botulinum toxin compositions
PCT/US2003/021351 WO2004006954A2 (en) 2002-07-11 2003-07-08 Transdermal botulinum toxin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010214831A Division JP2011037866A (ja) 2002-07-11 2010-09-27 経皮ボツリヌス毒素組成物

Publications (2)

Publication Number Publication Date
JP2005538082A JP2005538082A (ja) 2005-12-15
JP2005538082A5 true JP2005538082A5 (https=) 2006-08-03

Family

ID=30114842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004521565A Pending JP2005538082A (ja) 2002-07-11 2003-07-08 経皮ボツリヌス毒素組成物
JP2010214831A Pending JP2011037866A (ja) 2002-07-11 2010-09-27 経皮ボツリヌス毒素組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010214831A Pending JP2011037866A (ja) 2002-07-11 2010-09-27 経皮ボツリヌス毒素組成物

Country Status (15)

Country Link
US (5) US20040009180A1 (https=)
EP (1) EP1521593B1 (https=)
JP (2) JP2005538082A (https=)
KR (1) KR101041698B1 (https=)
CN (1) CN100546648C (https=)
AT (1) ATE430579T1 (https=)
AU (1) AU2003267987B2 (https=)
BR (1) BR0312506A (https=)
CA (1) CA2492029A1 (https=)
DE (1) DE60327528D1 (https=)
DK (1) DK1521593T3 (https=)
ES (1) ES2323497T3 (https=)
MX (1) MXPA05000134A (https=)
NZ (1) NZ537231A (https=)
WO (1) WO2004006954A2 (https=)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US9066943B2 (en) * 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
WO2004084839A2 (en) * 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
BRPI0508410B8 (pt) * 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20080031898A1 (en) * 2004-03-26 2008-02-07 David Nathaniel E Compositions and methods to increase the effect of a neurotoxin treatment
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
JP2007536269A (ja) * 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2266599B1 (en) * 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7906124B2 (en) * 2004-09-18 2011-03-15 Asthmatx, Inc. Inactivation of smooth muscle tissue
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
EP1833571B1 (en) * 2004-12-29 2011-04-27 LABO Cosprophar AG Cosmetic composition for skin application suitable for relaxing expression wrinkles
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
MX2007010674A (es) * 2005-03-03 2007-11-08 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido.
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
EP1747782A1 (en) 2005-07-19 2007-01-31 Cesare Montecucco Products for topical application comprising lysophospholipids and fatty acids
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7608275B2 (en) 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN103126971A (zh) * 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
KR102110379B1 (ko) 2005-12-01 2020-05-14 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2013234398B2 (en) * 2005-12-01 2016-05-19 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101374860A (zh) 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US8658391B2 (en) * 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US7445783B2 (en) * 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
US8961877B2 (en) * 2007-08-09 2015-02-24 Massachusetts Institute Of Technology High-throughput, whole-animal screening system
MX2010004502A (es) * 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
US8697155B2 (en) * 2008-07-22 2014-04-15 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
DE102008034453A1 (de) * 2008-07-24 2010-02-11 Lts Lohmann Therapie-Systeme Ag Verfahren zum Herstellen eines Mehrschichtenverbundes auf einer CIP-fähigen Beschichtungsanlage und Verwendung des damit hergestellten Mehrschichtenverbundes für die transdermale Applikation oder die Applikation in Körperhöhlen
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
HUE037595T2 (hu) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injektálható botulinum toxin készítmények
EP2413947B1 (en) * 2009-04-01 2020-04-29 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
EP2926757B1 (en) 2009-10-27 2023-01-25 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
US20120328701A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
BR112013018918A2 (pt) 2011-01-24 2016-10-04 Anterios Inc composições de nanopartículas
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
BR112013033363A2 (pt) * 2011-06-27 2017-01-31 Duck Kim Sang composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma
WO2016028811A1 (en) * 2014-08-18 2016-02-25 Nova Neura, Llc Pain relieving system
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
CA2869599C (en) 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
GB201208384D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US9205204B2 (en) 2012-08-06 2015-12-08 Elwha Llc Devices and methods for wearable injection guides
RU2506054C1 (ru) * 2012-10-22 2014-02-10 Елена Александровна Рогожкина Способ лечения хронической анальной трещины
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014147255A1 (en) 2013-03-22 2014-09-25 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US20160279401A1 (en) 2015-03-27 2016-09-29 Allergan, Inc. Dissolvable microneedles for skin treatment
KR101882461B1 (ko) * 2014-05-29 2018-07-27 주식회사 프로셀테라퓨틱스 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016167545A1 (ko) * 2015-04-13 2016-10-20 주식회사 엘지생활건강 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들
CN107427474A (zh) 2015-04-13 2017-12-01 株式会社Lg生活健康 含有调节神经递质释放的成分的可溶性微针
KR102203633B1 (ko) * 2015-04-14 2021-01-15 주식회사 엘지생활건강 칼슘채널 차단제 전달용 용해성 미세바늘
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
WO2017063743A1 (en) * 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
US20170209553A1 (en) * 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
KR101876177B1 (ko) * 2016-02-17 2018-07-09 가톨릭관동대학교산학협력단 경피투과 보툴리눔 독소 패치
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
AU2018222745B2 (en) 2017-02-17 2021-02-18 Allergan, Inc. Microneedle array with active ingredient
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINARY NEUROTOXINS FOR USE IN THERAPY
CN106890196A (zh) * 2017-04-07 2017-06-27 青岛东海药业有限公司 酪酸梭菌在制备预防或治疗帕金森病制剂中的应用
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
AU2018389104A1 (en) 2017-12-20 2020-07-30 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
CN111195230B (zh) * 2018-11-19 2024-01-12 奥维嘉生物科技（北京）有限公司 一种制备柔性脂质体的方法
MX2021006102A (es) 2018-12-03 2021-09-21 Eirion Therapeutics Inc Suministro mejorado de agentes grandes.
MX2021009993A (es) * 2019-02-20 2021-10-26 Regresar Medical Inc Metodos y dispositivos para localizar composiciones.
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
US20220296503A1 (en) * 2019-05-14 2022-09-22 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
WO2026053109A1 (en) * 2024-09-03 2026-03-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Methods for enhancing transdermal delivery of botulinum toxins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
USD296006S (en) * 1985-06-20 1988-05-31 Ciba-Geigy Corporation Multicompartmentalized transdermal patch for administering drugs to the skin
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) * 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
DE69428813T2 (de) * 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5587396A (en) * 1994-08-26 1996-12-24 Mary Kay Inc. Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
EP0773788B1 (en) * 1995-06-06 2003-05-07 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
AU725269B2 (en) * 1995-07-25 2000-10-12 Massachusetts Institute Of Technology Enhanced transdermal transport using ultrasound
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
EP1045714A1 (en) 1998-01-08 2000-10-25 Sontra Medical, L.P. Sonophoretic enhanced transdermal transport
ATE365050T1 (de) * 1998-02-25 2007-07-15 Us Gov Sec Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der transkutanen immunantwort
US5965154A (en) * 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19852981A1 (de) * 1998-11-17 2000-05-18 Martin Schmidt Botulinum-Toxine, deren Derivate, Analoge und molekulare Bruchstücke zur topischen epicutanen Anwendung auch in Zusammenwirken mit hautpenetrationsfördernden Substanzen und Maßnahmen in Zubereitungsformen zur Beeinflussung acetylcholinabhängiger Körperfunktionen
US6238683B1 (en) * 1998-12-04 2001-05-29 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
DE60143571D1 (de) * 2000-05-26 2011-01-13 Kanji Takada Nicht-orale zubereitung mit einer dreischicht-struktur
US6565532B1 (en) * 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
KR20140012651A (ko) * 2011-01-24 2014-02-03 안테리오스, 인코퍼레이티드 파라벤 조성물

Similar Documents

Publication Publication Date Title
JP2005538082A5 (https=)
JP2018525123A5 (https=)
JP2012041355A5 (https=)
Gao et al. How physical techniques improve the transdermal permeation of therapeutics: A review
CN110494114A (zh) 皮肤的美容外观
JP2005245521A (ja) イオン導入器、超音波美顔器並びに化粧品添加物を使用する美肌又は美容システム。
JP2003325532A (ja) ヒト皮膚の剥離システム及びその方法
GB2571668A (en) Stem cell conditioned media for clinical and cosmetic applications
CN105813682A (zh) 剪切引发的表皮注入
SantoiannI et al. Intradermal drug delivery by low frequency sonophoresis (25KHz)
KR20200002429U (ko) 피부 미용, 화장품용 및 의료용 기기
CN104856914A (zh) 乏血小板血浆在皮肤护理中的应用
EP3501592A1 (en) Non-invasive delivery method
Ko et al. Clinical Efficacy and Safety of Low‐Energy Extracorporeal Shock Wave Therapy for Various Conditions of Deep Dermal and Subdermal Fibrosis
CN103393854B (zh) 一种神灸植物精油及制备方法及应用
KR20100094700A (ko) 마이크로니들 스탬프와 연동된 치료 및 스킨케어 시스템
CN201906172U (zh) 一种按摩美容棒
ATE326200T1 (de) Einbringen von kosmetika in die haut
RU2279269C2 (ru) Способ выполнения массажа
KR101683839B1 (ko) 오존크림 고속 제조장치
WO2026057975A1 (en) Force inducing, vibrating face mask
JP2004231627A (ja) 重水素減少水（スーパーライトウォーター）を利用した湿布、パックによるシワ、クスミ、イボ、皮膚がん、赤アザの治療方法
CN211797615U (zh) 一种设置有转动盘的刮痧板
KR20240130977A (ko) 고밀도 집속 초음파 기능과 리프팅 기능이 결합된 종합 미용기기
JP6481087B2 (ja) パーマネント方法を利用した発汗促進方法